Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283

William Petersen, Jingbo Liu, Liangping Yuan, Hongying Zhang, Matthew Schneiderjan, Yoon-Jae Cho, Tobey J. MacDonald

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Medulloblastoma (MB) expresses Src kinase, while aurora kinase A overexpression correlates with poor survival. We thus investigated novel combination treatment with dasatinib and AT9283, inhibitors of Src and aurora kinase, respectively, on MB growth in vitro and in vivo. Treatment with each drug significantly reduced cell viability and combined treatment markedly potentiated this response. AT9283 induced p53 expression, autophagy, and G2/M cell-cycle arrest, while combined treatment induced S phase arrest. Dasatinib treatment caused tumor regression in vivo. Activated Src was detected in 44% MB analyzed. We conclude that further evaluation of this combination therapy for MB is highly warranted.

Original languageEnglish (US)
Pages (from-to)68-76
Number of pages9
JournalCancer Letters
Volume354
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Aurora Kinases
Medulloblastoma
src-Family Kinases
Aurora Kinase A
G2 Phase Cell Cycle Checkpoints
Autophagy
S Phase
Cell Survival
1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea
Dasatinib
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Aurora kinase
  • Dasatinib
  • Medulloblastoma
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. / Petersen, William; Liu, Jingbo; Yuan, Liangping; Zhang, Hongying; Schneiderjan, Matthew; Cho, Yoon-Jae; MacDonald, Tobey J.

In: Cancer Letters, Vol. 354, No. 1, 01.01.2014, p. 68-76.

Research output: Contribution to journalArticle

Petersen, William ; Liu, Jingbo ; Yuan, Liangping ; Zhang, Hongying ; Schneiderjan, Matthew ; Cho, Yoon-Jae ; MacDonald, Tobey J. / Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. In: Cancer Letters. 2014 ; Vol. 354, No. 1. pp. 68-76.
@article{b597703856bb4d9fab3cdbf9acd74cb8,
title = "Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283",
abstract = "Medulloblastoma (MB) expresses Src kinase, while aurora kinase A overexpression correlates with poor survival. We thus investigated novel combination treatment with dasatinib and AT9283, inhibitors of Src and aurora kinase, respectively, on MB growth in vitro and in vivo. Treatment with each drug significantly reduced cell viability and combined treatment markedly potentiated this response. AT9283 induced p53 expression, autophagy, and G2/M cell-cycle arrest, while combined treatment induced S phase arrest. Dasatinib treatment caused tumor regression in vivo. Activated Src was detected in 44{\%} MB analyzed. We conclude that further evaluation of this combination therapy for MB is highly warranted.",
keywords = "Aurora kinase, Dasatinib, Medulloblastoma, Survival",
author = "William Petersen and Jingbo Liu and Liangping Yuan and Hongying Zhang and Matthew Schneiderjan and Yoon-Jae Cho and MacDonald, {Tobey J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2014.07.038",
language = "English (US)",
volume = "354",
pages = "68--76",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283

AU - Petersen, William

AU - Liu, Jingbo

AU - Yuan, Liangping

AU - Zhang, Hongying

AU - Schneiderjan, Matthew

AU - Cho, Yoon-Jae

AU - MacDonald, Tobey J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Medulloblastoma (MB) expresses Src kinase, while aurora kinase A overexpression correlates with poor survival. We thus investigated novel combination treatment with dasatinib and AT9283, inhibitors of Src and aurora kinase, respectively, on MB growth in vitro and in vivo. Treatment with each drug significantly reduced cell viability and combined treatment markedly potentiated this response. AT9283 induced p53 expression, autophagy, and G2/M cell-cycle arrest, while combined treatment induced S phase arrest. Dasatinib treatment caused tumor regression in vivo. Activated Src was detected in 44% MB analyzed. We conclude that further evaluation of this combination therapy for MB is highly warranted.

AB - Medulloblastoma (MB) expresses Src kinase, while aurora kinase A overexpression correlates with poor survival. We thus investigated novel combination treatment with dasatinib and AT9283, inhibitors of Src and aurora kinase, respectively, on MB growth in vitro and in vivo. Treatment with each drug significantly reduced cell viability and combined treatment markedly potentiated this response. AT9283 induced p53 expression, autophagy, and G2/M cell-cycle arrest, while combined treatment induced S phase arrest. Dasatinib treatment caused tumor regression in vivo. Activated Src was detected in 44% MB analyzed. We conclude that further evaluation of this combination therapy for MB is highly warranted.

KW - Aurora kinase

KW - Dasatinib

KW - Medulloblastoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84910019544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910019544&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2014.07.038

DO - 10.1016/j.canlet.2014.07.038

M3 - Article

C2 - 25107642

AN - SCOPUS:84910019544

VL - 354

SP - 68

EP - 76

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -